Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the same outcomes as the original-brand reference...
Saved in:
| Main Authors: | Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | Therapeutic Advances in Musculoskeletal Disease |
| Online Access: | https://doi.org/10.1177/1759720X251335147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis
by: Rajesh B. Singh, et al. -
MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects
by: Monika Tomaszewska‐Kiecana, et al.
Published: (2024-09-01) -
Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab
by: Seungchan Choi, et al.
Published: (2025-08-01) -
Osteoporosis in axial radiographic spondyloarthritis: diagnostic limitations of bone mineral density and the need for comprehensive fracture risk assessment
by: Paweł Żuchowski, et al.
Published: (2024-12-01) -
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors
by: Mingchuan Zhao, et al.
Published: (2025-04-01)